Global Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics to improve the lives of patients with grievous blood-based disorders. 

GBT440, our lead drug candidate, is an oral, once-daily prophylactic therapy for patients with sickle cell disease (SCD).  GBT440 targets the underlying mechanism of red blood cell sickling, which we believe provides the potential to treat SCD rather than only its associated symptoms.  GBT440 is currently being investigated in an ongoing Phase 1/2 clinical trial in both healthy subjects and SCD patients.

In addition, GBT plans to develop GBT440 or one of its analogs as a potential therapy for acute and chronic hypoxemic lung disorders, including idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS).  We are also working on an oral kallikrein inhibitor to prevent hereditary angioedema (HAE) attacks.

GBT was launched in 2012 with funding from leading healthcare investor Third Rock Ventures.